Alkem Labs - Beneficiary Of Strong Recovery In Acute Portfolio: ICICI Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Alkem Laboratories Ltd. has seen strong growth recovery in its acute portfolio during Q1 FY22 as per All Indian Origin Chemists and Distributors (secondary sales) data and its better than industry growth.
The anti-infectives and gastro-intestinal, the two largest therapeutic segments for Alkem Laboratories, have witnessed healthy ramp-up.
Additionally, we believe the growth in FY22E may show positive surprise considering the low base of FY21 and if the momentum of this sharp recovery in acute segments continues.
We remain positive on the long-term outlook based on sustainable growth in the domestic market and gradual scale-up in U.S. generic business coupled with an improving margin profile.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.